Regeneron Pharmaceuticals, Inc. is adding more than 400 new jobs at its Industrial Operations and Product Supply (IOPS) campus in Limerick, Ireland, bringing total headcount to over 1,400.

The new jobs will support the production of Regeneron’s existing medicines. The company is maximizing manufacturing capacity at its New York facility for REGN-COV2, Regeneron’s investigational two-antibody combination being developed for the potential treatment and prevention of COVID-19 infection.

Since 2014, Regeneron has invested more than $1 billion to build the largest bulk biologics production facility in Ireland, with more than 1,000 employees. Recruitment is underway to hire full-time, high-end specialist jobs in commercial manufacturing, process sciences, quality assurance/control, supply chain and various support functions for scientists, chemists and technicians.

Dan Van Plew, Executive Vice President & General Manager of IOPS at Regeneron said, “As this pandemic hit, we needed to quickly change how we do things and where we make our products. In order to make space in our New York facilities to accommodate our COVID-19 efforts, we needed to ramp-up capacity here in Limerick. Despite ramping up commercial production sooner than planned, my team hasn’t missed a beat. You can only perform like this if you have good people, and Ireland has lots of good people, so we are excited to be hiring 400 more.”

Visit www.regeneron.ie to learn more and see a current list of job openings in Ireland.